{
    "clinical_study": {
        "@rank": "53761", 
        "arm_group": [
            {
                "arm_group_label": "PAC-14028 cream 0.3%", 
                "arm_group_type": "Experimental", 
                "description": "PAC-14028 cream 0.3%, twice daily for 28 days"
            }, 
            {
                "arm_group_label": "PAC-14028 cream 1.0%", 
                "arm_group_type": "Experimental", 
                "description": "PAC-14028 cream 1.0%, twice daily for 28days"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle, twice daily for 28days"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study was to find a clinically appropriate dose of PAC-14028 cream by\n      comparatively evaluating the efficacy and safety of PAC-14028 cream of Amorepacific\n      Corporation in patients with dermal pruritus."
        }, 
        "brief_title": "Efficacy and Safety Study of PAC-14028 Cream in Dermal Pruritus", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Skin Pruritus", 
        "condition_browse": {
            "mesh_term": "Pruritus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients at the age of 20 to 65 years old (both inclusive)\n\n          -  Pruritus test \u2265 5cm (10cm Visual Analogue Scale [VAS]) at baseline\n\n          -  Eczema or dry skin on the study drug application site\n\n          -  Women of childbearing potential should have a negative urine pregnancy test at\n             screening and agree to employ an effective method of birth control (surgical\n             sterilization or oral contraceptives, barrier method with spermicides, intrauterine\n             device, etc.) during the study period.\n\n          -  Voluntarily signed written informed consent forms for study participation.\n\n        Exclusion Criteria:\n\n          -  Pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or\n             neuropathic causes rather than as a skin disease.\n\n          -  Chronic skin diseases such as malignant tumor or chronic urticaria, among skin\n             diseases.\n\n          -  Simple pruritus caused by allergic substances such as scabies or insect bites.\n\n          -  Presence of symptoms of generalized infection at the time of study participation.\n\n          -  Previous local treatment or antibiotics administration for pruritus within 7 days\n             prior to study participation.\n\n          -  Previous use of oral steroids within 1 month and local steroids within 2 weeks prior\n             to study participation.\n\n          -  History of physical treatment for pruritus, including phototherapy, within 1 month\n             prior to study participation.\n\n          -  Patients who are treated with prohibited concomitant drugs or considered to\n             inevitably require treatment with prohibited concomitant drugs during the study\n             period.\n\n          -  Renal function impairment with creatinine level\n\n          -  Hepatic function impairment with aspartate aminotransferase (AST)/ alanine\n             aminotransferase (ALT)\n\n          -  Pregnant and lactating women\n\n          -  Participation in another clinical study within 1 month prior to screening.\n\n          -  Patients considered ineligible for study participation by the principal investigator\n             or sub-investigator for other reasons; pruritus due to other medical (liver disease,\n             renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052531", 
            "org_study_id": "AP-TRPV1_PII-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PAC-14028 cream 0.3%", 
                    "PAC-14028 cream 1.0%"
                ], 
                "description": "Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks", 
                "intervention_name": "PAC-14028", 
                "intervention_type": "Drug", 
                "other_name": [
                    "PAC-14028 Cream 0.3%", 
                    "PAC-14028 Cream 1.0%"
                ]
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Participants received topical Vehicle twice daily for 4 weeks", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Other", 
                "other_name": "Vehicle of PAC-14028 Cream"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Kyu-Han Kim"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Single Center, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of PAC-14028 Cream in Dermal Pruritus", 
        "overall_official": {
            "affiliation": "Department of Dermatology, Seoul National University Hospital", 
            "last_name": "Kyu-Han Kim, MD,Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patient reported outcome of pruritis measurement on a change in visual analog scale", 
            "measure": "Change in Visual Analog Scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline through Study Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052531"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Treatment success rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Study Day 28"
            }, 
            {
                "measure": "Change in specified symptom sum score (SRRC) Index", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Study Day 28"
            }, 
            {
                "measure": "Change in transepidermal water loss", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Study Day 28"
            }, 
            {
                "measure": "Change in skin hydration", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Study Day 28"
            }
        ], 
        "source": "Amorepacific Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amorepacific Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}